Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Rhea-AI Summary

OSR Holdings (NASDAQ: OSRH) announced that Woori IO shareholders approved a share exchange at an Extraordinary General Meeting on Dec 19, 2025, which will make Woori IO a wholly-owned subsidiary of OSRK upon completion.

Woori IO is running a Samsung-supported PoC study in Korea aimed at Korean regulatory approval for its noninvasive blood glucose monitoring platform, and has received an invitation from a leading California research university to collaborate on a U.S. FDA clinical trial to support U.S. market development.

Positive

• Share exchange approved at EGM on Dec 19, 2025
• Woori IO to become wholly-owned subsidiary of OSRK upon completion
• Samsung-supported PoC study underway in Korea
• Invitation to collaborate on U.S. FDA clinical trial from California research university

Negative

• Share exchange requires completion to finalize ownership change
• No Korean or U.S. regulatory approvals yet; trials are ongoing/planned

Market Reality Check

$0.6510 Last Close

Volume Volume 359,325 is well below the 20-day average of 10,993,708, suggesting limited participation in the move. low

Technical Price 0.5728 is trading below the 200-day moving average of 1.04 and far under the 10.00 52-week high.

Peers on Argus

Peers show mixed moves: ADAP -17.57%, APLM -4.06%, APM +1.9%, PHGE +9.3%, PHIO +0.95%. OSRH’s +5.62% gain appears more company-specific than sector-driven.

Market Pulse Summary

The stock surged +13.7% in the session following this news. A strong positive reaction aligns with completion of the Woori IO share exchange, which finalizes its integration as a wholly-owned subsidiary and supports dual clinical pathways in Korea and the U.S. Despite trading well below the 10.00 52-week high and under the 1.04 200-day MA, investors may have focused on the strategic move into noninvasive glucose monitoring and planned U.S. FDA trial collaboration.

Key Terms

proof-of-concept medical

"collaborating with Samsung Electronics on a Proof-of-Concept ("PoC") study in South Korea"

A proof-of-concept is a demonstration that shows a new idea or method can work as intended, serving as a small-scale test before full development. For investors, it signals that a concept has been successfully tested in principle, reducing uncertainty about whether it can be practically implemented. This helps determine if further investment or effort is justified to develop the idea further.

noninvasive glucose monitoring medical

"medical device innovator in noninvasive glucose monitoring technology, approved a share exchange"

A method or device that measures a person’s blood sugar level without piercing the skin or drawing blood, typically using external sensors or light-based techniques. For investors, it matters because successful noninvasive monitoring could unlock a large consumer and medical market by making glucose checks easier, cheaper and more frequent—similar to checking tire pressure without removing the cap—affecting sales, adoption rates and regulatory risk for companies developing the technology.

u.s. fda clinical trial regulatory

"invitation from a prestigious research university to collaborate on a U.S. FDA clinical trial"

A U.S. FDA clinical trial is a regulated study conducted in the United States to test whether a drug, vaccine, or medical device is safe and effective for people, overseen by the Food and Drug Administration. Investors care because trial results drive whether a product can reach the market, shape its potential sales and costs, and create big swings in a company’s value—much like a final road test determining if a new car can be sold widely.

AI-generated analysis. Not financial advice.

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leading California research university

BELLEVUE, Wash., Dec. 19, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) ("OSR Holdings"), a global healthcare holding company, today announced that the shareholders of Woori IO Co., Ltd. ("Woori IO"), a leading Korean medical device innovator in noninvasive glucose monitoring technology, approved a share exchange at an Extraordinary General Meeting ("EGM") held at Woori IO's headquarters in Jeonju, Korea. The approved share exchange will result in Woori IO becoming a wholly-owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), the Korean intermediate holding company of OSR Holdings, Inc.

Upon completion of the share exchange, Woori IO will become a wholly-owned subsidiary of OSRK, marking the final step in a sequence of corporate actions designed to integrate Woori IO fully into the OSR Group ecosystem.

Woori IO is currently collaborating with Samsung Electronics on a Proof-of-Concept ("PoC") study in South Korea aimed at achieving Korean regulatory approval for its breakthrough noninvasive blood glucose monitoring platform.

With the corporate combination now finalized, Woori IO also plans to initiate U.S. market development activities, supported by an invitation from a prestigious research university to collaborate on a U.S. FDA clinical trial for Woori IO's technology. This collaboration is expected to serve as a foundation for advancing Woori IO's regulatory and commercial strategy in the United States.

"Integrating Woori IO into OSR Group strengthens the foundation for global expansion," said Peter Hwang, CEO of OSR Holdings. "We look forward to supporting Woori IO as it advances its regulatory pathways in Korea and begins its U.S. clinical initiatives. Their breakthrough noninvasive glucose monitoring technology represents a major step toward improving metabolic health worldwide."

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding anticipated regulatory activities, clinical development plans, market expansion, strategic collaborations, and expected benefits from the integration of Woori IO into OSR Group. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, regulatory approval processes, clinical trial outcomes, operational challenges, market conditions, integration risks, and other factors described in OSR Holdings, Inc.'s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings and Woori IO undertake no obligation to update or revise forward-looking statements, except as required by law.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its vision is to build a portfolio of breakthrough healthcare solutions to improve global health outcomes. Learn more at www.OSR-Holdings.com.

About Woori IO Co., Ltd.

Woori IO is a South Korea-based medical device company developing noninvasive biosensing technologies for glucose monitoring and beyond. Its proprietary NIRS-based system enables accurate, pain-free glucose tracking and is designed for integration into wearables. The company has been recognized by a leading global consumer electronics company's startup program for its innovation in NIGM technology.

 

 

View original content:https://www.prnewswire.com/news-releases/woori-io-shareholders-approve-share-exchange-to-become-wholly-owned-subsidiary-of-osr-holdings-302647107.html

SOURCE OSR Holdings Inc.

FAQ

What did OSR Holdings (OSRH) announce on Dec 19, 2025 about Woori IO?

OSR Holdings announced Woori IO shareholders approved a share exchange that will make Woori IO a wholly-owned subsidiary of OSRK upon completion.

How will the Woori IO share exchange affect OSR Holdings (OSRH) ownership?

The approved share exchange will transfer full ownership of Woori IO to OSRK, the Korean intermediate holding company of OSR Holdings, upon completion.

What clinical programs does Woori IO have after the OSRH announcement?

Woori IO is conducting a Samsung-supported PoC study in Korea and plans a U.S. FDA clinical trial collaboration with a California research university.

Does the OSRH announcement state Woori IO has regulatory approval in Korea or the U.S.?

No; the announcement describes a PoC aimed at Korean regulatory approval and a planned U.S. FDA clinical trial, but does not report approvals.

When will Woori IO become a wholly-owned subsidiary of OSRK under OSRH?

Woori IO will become a wholly-owned subsidiary upon completion of the approved share exchange following the EGM held Dec 19, 2025.